FDA Weighs Skin Risks of Bayer AG Imaging Drug
(Reuters) - U.S. advisers will be asked to focus on the potential for overdoses from a Bayer AG imaging drug when they review the product on Friday. Food and Drug Administration staff, in documents released on Wednesday, said they wanted input from the panel of outside experts on risks of nephrogenic systemic fibrosis (NSF), a potentially fatal skin disorder seen with similar drugs.